Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2010

01-05-2010 | Original Article

The Role of Nitric Oxide in the Expression of Renal Aquaporin 2 in a Cirrhotic Rat Model: Does an AVP-Independent Mechanism Exist for the Regulation of AQP2 Expression?

Authors: Dae Won Jun, Jin Hee Park, Yoo Sin Park, Ju-Seop Kang, Eun Kyung Kim, Kyung Tae Kim, Byoung Kwan Son, Seong Hwan Kim, Yun Ju Jo, Young Sook Park

Published in: Digestive Diseases and Sciences | Issue 5/2010

Login to get access

Abstract

The aquaporin (AQP) water channel is expected to play a decisive role of hyponatremia and water retention in cirrhotic patients. Despite the importance of the water channel, however, previous findings vary widely when it concerns AQP2 of the kidneys in subjects with cirrhosis. The purpose of this study was to investigate the expression of AQP2 in the distal renal tubule in cirrhosis, and the presence of the nitric oxide-AQP2 signaling pathway as a possible vasopressin-aquaporin-independent pathway. Sixty male Wister rats were assigned to six groups: (1) control; (2) TAA (thioacetamide); (3) TAA with nitric oxide donor; (4) TAA with nitric oxide inhibitor; (5) TAA with HMG CoA reductase inhibitor; (6) TAA with tetrahydrobiopterin. Immunohistochemical staining for AQP2, real-time polymerase chain reaction (PCR) for AQP2 and 3, citrulline assay, and renal cGMP concentration were measured. The AQP2-positivity of cirrhotic rats were higher than the controls (P < 0.05). The AQP2-positivity decreased in the nitric oxide donor group, but the proportion rose back up when the subjects were injected with the nitric oxide inhibitor (P < 0.05). The expression of AQP2 and AQP3 mRNA was also found to show an increase in the cirrhotic group as compared with the normal controls (P < 0.05). The cirrhotic group administered with nitric oxide donor showed a significant decline in the expression of the mRNA. The control group’s cGMP concentration was lower than that of the cirrhotic group (P < 0.05), but a comparison of the two groups injected with nitric oxide modulators, such as statin and BH4, did not show significant differences in the cGMP concentration level. The expression of AQP2 of the kidneys increased in the cirrhotic rats. AQP2 had relations to the activity changes of nitric oxide synthetase.
Literature
1.
3.
5.
go back to reference Fernández-Llama P. Aquaporins and renal water metabolism. Role in the physiopathology of water retention in cirrhosis. Gastroenterol Hepatol. 2001;24:205–209.PubMed Fernández-Llama P. Aquaporins and renal water metabolism. Role in the physiopathology of water retention in cirrhosis. Gastroenterol Hepatol. 2001;24:205–209.PubMed
7.
go back to reference Fujita N, Ishikawa SE, Sasaki S, et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 1995;269:F926–F931.PubMed Fujita N, Ishikawa SE, Sasaki S, et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 1995;269:F926–F931.PubMed
8.
go back to reference Jonassen TE, Nielsen S, Christensen S, et al. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol. 1998;275:F216–F225.PubMed Jonassen TE, Nielsen S, Christensen S, et al. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol. 1998;275:F216–F225.PubMed
9.
go back to reference Fernández-Llama P. Molecular bases for water/salt retention in experimental liver cirrhosis: aquaporins and renal sodium transporters. Nefrologia. 2002;22(Suppl 5):29–33.PubMed Fernández-Llama P. Molecular bases for water/salt retention in experimental liver cirrhosis: aquaporins and renal sodium transporters. Nefrologia. 2002;22(Suppl 5):29–33.PubMed
11.
go back to reference Esteva-Font C, Baccaro ME, Fernández-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44:1555–1563. doi:10.1002/hep.21414.CrossRefPubMed Esteva-Font C, Baccaro ME, Fernández-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44:1555–1563. doi:10.​1002/​hep.​21414.CrossRefPubMed
13.
go back to reference Pérez-Ayuso RM, Arroyo V, Camps J, et al. Effect of demeclocycline on renal function and urinary prostaglandin e2 and kallikrein in hyponatremic cirrhotics. Nephron. 1984;36:30–37. doi:10.1159/000183112.CrossRefPubMed Pérez-Ayuso RM, Arroyo V, Camps J, et al. Effect of demeclocycline on renal function and urinary prostaglandin e2 and kallikrein in hyponatremic cirrhotics. Nephron. 1984;36:30–37. doi:10.​1159/​000183112.CrossRefPubMed
14.
go back to reference Jiménez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther. 2000;295:83–90.PubMed Jiménez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther. 2000;295:83–90.PubMed
15.
go back to reference Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191. doi:10.1053/jhep.2003.50021.CrossRefPubMed Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191. doi:10.​1053/​jhep.​2003.​50021.CrossRefPubMed
20.
21.
go back to reference Bouley R, Breton S, Sun T, et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest. 2000;106:1115–1126. doi:10.1172/JCI9594.CrossRefPubMed Bouley R, Breton S, Sun T, et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest. 2000;106:1115–1126. doi:10.​1172/​JCI9594.CrossRefPubMed
22.
25.
go back to reference Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235–242. doi:10.1172/JCI626.CrossRefPubMed Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235–242. doi:10.​1172/​JCI626.CrossRefPubMed
26.
go back to reference Matei V, Rodríguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44:44–52. doi:10.1002/hep.21228.CrossRefPubMed Matei V, Rodríguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44:44–52. doi:10.​1002/​hep.​21228.CrossRefPubMed
Metadata
Title
The Role of Nitric Oxide in the Expression of Renal Aquaporin 2 in a Cirrhotic Rat Model: Does an AVP-Independent Mechanism Exist for the Regulation of AQP2 Expression?
Authors
Dae Won Jun
Jin Hee Park
Yoo Sin Park
Ju-Seop Kang
Eun Kyung Kim
Kyung Tae Kim
Byoung Kwan Son
Seong Hwan Kim
Yun Ju Jo
Young Sook Park
Publication date
01-05-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0852-y

Other articles of this Issue 5/2010

Digestive Diseases and Sciences 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.